

*In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model*

Eleni Kolokotroni, Dimitra Dionysiou, Christian Veith, Yoo-Jin Kim, Jörg Sabczynski, Astrid Franz, Aleksandar Grgic, Jan Palm, Rainer M. Bohle, Georgios Stamatakos

**S1 Table**  
**Supplemental PRCC analyses**

Analysis A			Analysis B		
Feature	PRCC	p-value	Feature	PRCC	p-value
Stem/LIMP	0.129	2.47*10 <sup>-3</sup>	Stem/DIFF	0.113	7.97*10 <sup>-3</sup>
LIMP/Living	0.131	2.11*10 <sup>-3</sup>	LIMP/Living	0.111	9.08*10 <sup>-3</sup>
Growth Fraction	-0.487	6.00*10 <sup>-34</sup>	Growth Fraction	-0.489	3.73*10 <sup>-34</sup>
Quiescent/Living	-0.0823	0.0544	Quiescent/Living	-0.0845	0.0482
Apoptotic/Total	0.0187	0.663	Apoptotic/Total	0.0184	0.667
Necrotic/Total	0.121	4.76*10 <sup>-3</sup>	Necrotic/Total	0.120	4.90*10 <sup>-3</sup>
T <sub>d</sub>	-0.813	2.62*10 <sup>-130</sup>	T <sub>d</sub>	-0.813	2.20*10 <sup>-130</sup>

Values rounded to three significant figures

DIFF: terminally differentiated tumor cell, LIMP: Limited Mitotic Potential tumor cell, T<sub>d</sub>: volume doubling time